Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lurdes Y T Inoue

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Journal of the American Statistical Association|February 13, 2010
Joint modeling of self-rated health and changes in physical functioningRebecca A Hubbard, Lurdes Y T Inoue, Paula Diehr
Biometrics|December 24, 2002
Seamlessly expanding a randomized phase II trial to phase IIILurdes Y T Inoue, Peter F Thall, Donald A Berry
Journal of the American Statistical Association|January 24, 2014
Modeling Disease Progression with Longitudinal MarkersLurdes Y T Inoue, Ruth Etzioni, Christopher Morrell, et al.
Biometrics|September 17, 2002
Adaptive decision making in a lymphocyte infusion trialPeter F Thall, Lurdes Y T Inoue, Thomas G Martin
Biostatistics (Oxford, England)|September 19, 2006
Cluster-based network model for time-course gene expression dataLurdes Y T Inoue, Mauricio Neira, Colleen Nelson, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 4, 2021
Recalibration Methods for Improved Clinical Utility of Risk ScoresAnu Mishra, Robyn L McClelland, Lurdes Y T Inoue, et al.
Biometrics|October 17, 2014
A joint model for multistate disease processes and random informative observation times, with applications to electronic medical records dataJane M Lange, Rebecca A Hubbard, Lurdes Y T Inoue, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 10, 2025
Author Reply: Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case StudyYilin Chen, Peter Martin, Lurdes Y T Inoue, et al.
Statistics in Medicine|July 19, 2005
Continuous Bayesian adaptive randomization based on event times with covariatesYing Kuen Cheung, Lurdes Y T Inoue, J Kyle Wathen, et al.
Journal of the National Cancer Institute|January 9, 2014
Individualized estimates of overdiagnosis in screen-detected prostate cancerRoman Gulati, Lurdes Y T Inoue, John L Gore, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Journal of the American Statistical Association|February 13, 2010
Joint modeling of self-rated health and changes in physical functioningRebecca A Hubbard, Lurdes Y T Inoue, Paula Diehr
Biometrics|December 24, 2002
Seamlessly expanding a randomized phase II trial to phase IIILurdes Y T Inoue, Peter F Thall, Donald A Berry
Journal of the American Statistical Association|January 24, 2014
Modeling Disease Progression with Longitudinal MarkersLurdes Y T Inoue, Ruth Etzioni, Christopher Morrell, et al.
Biometrics|September 17, 2002
Adaptive decision making in a lymphocyte infusion trialPeter F Thall, Lurdes Y T Inoue, Thomas G Martin
Biostatistics (Oxford, England)|September 19, 2006
Cluster-based network model for time-course gene expression dataLurdes Y T Inoue, Mauricio Neira, Colleen Nelson, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 4, 2021
Recalibration Methods for Improved Clinical Utility of Risk ScoresAnu Mishra, Robyn L McClelland, Lurdes Y T Inoue, et al.
Biometrics|October 17, 2014
A joint model for multistate disease processes and random informative observation times, with applications to electronic medical records dataJane M Lange, Rebecca A Hubbard, Lurdes Y T Inoue, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 10, 2025
Author Reply: Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case StudyYilin Chen, Peter Martin, Lurdes Y T Inoue, et al.
Statistics in Medicine|July 19, 2005
Continuous Bayesian adaptive randomization based on event times with covariatesYing Kuen Cheung, Lurdes Y T Inoue, J Kyle Wathen, et al.
Journal of the National Cancer Institute|January 9, 2014
Individualized estimates of overdiagnosis in screen-detected prostate cancerRoman Gulati, Lurdes Y T Inoue, John L Gore, et al.
Pageof 5